Pharmaceutical Executive - Pharmaceutical news and analysis. Pharma management, sales, marketing & finance

ADVERTISEMENT

Previous Story Play / Pause Next Story
New & Noteworthy
Fools Rush In: The Importance of Pre-Acquisition Due Diligance
Long before a deal is signed in ink, a company's compliance and legal team should be involved in the vetting process, writes Severin Wirz.
Pharm Exec Global Digest: FDA & Social Media Special
Will the FDA's social media guidelines help your digital strategy to take off? Check out what they say — and what they mean— in the latest issue of Pharm Exec Global Digest
WebMD: The Patient Value Equation
WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.

Latest Pharm Exec Videos

Events
Facility Design, Innovation and Qualification
July 29, 2014 - July 31, 2014
Philadelphia, PA USA

Speed to Therapy
August 12, 2014 - August 13, 2014
Philadelphia, PA USA

8th Annual Forum on Transparency and Aggregate Spend
August 18, 2014 - August 20, 2014
Washington, DC USA

Pharmaceutical Care Management Association Releases Hep C Medicare Part D Impact Study
The Market Will Demand a Cheaper Alternative to Sovaldi
GSK Submits Malaria Vaccine Candidate for EMA Approval
Wearable Devices in Clinical Trials: Challenges and Opportunities
New "Blockbusters" Will Triple Acute Coronary Syndrome Market
Rebranding Risk-Based Monitoring in Clinical R&D
Europe ReflectorBe Careful What You Wish For: EFPIA's Integrated Strategy Proposals
Drug Development Jill WechslerNIH Translational Research Partnership Yields Promising Therapy
From the Editor William LooneyBIO 2014's Surprising Takeaway: The Peace Dividend
Patient Advocacy Leela BarhamIndustry Challenged: Do More for Teenagers with Cancer
 More
Survey
The FDA Safety & Innovation Act (FDASIA) was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
15%
Protecting the supply chain
35%
Expedited reviews of drug submissions
15%
More stakeholder involvement
5%
View Results
PHARM EXEC GLOBAL DIGEST
Pharmaceutical Executive Digest EuropeTo read the latest issue of Pharm Exec Global Digest
Click here. Click here to receive the Digest into your inbox every month.
Click here